# Classifying for HER2 Dependence to De-Escalate Neoadjuvant Chemotherapy in Patients With HER2+ Early Breast Cancer Undergoing HER2 Double-Blockade

> **NCT06068985** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Latin American Cooperative Oncology Group** · enrollment: 63 (estimated)

## Conditions studied

- Breast Cancer
- HER2-positive Breast Cancer

## Interventions

- **DRUG:** PHESGO

## Key facts

- **NCT ID:** NCT06068985
- **Lead sponsor:** Latin American Cooperative Oncology Group
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-09-05
- **Primary completion:** 2026-04
- **Final completion:** 2032-04
- **Target enrollment:** 63 (ESTIMATED)
- **Last updated:** 2026-02-12

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06068985

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06068985, "Classifying for HER2 Dependence to De-Escalate Neoadjuvant Chemotherapy in Patients With HER2+ Early Breast Cancer Undergoing HER2 Double-Blockade". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT06068985. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*